Gene therapy is currently limited by the lack of a non-invasive and clinically useful means to monitor vector persistence and biodistribution and transgene expression in vivo. The goal of the current project is to test strategies devised to improve the spatial distribution of gene expression following the local administration of adenovirus-mediated gene therapy so that the entire organ receives a viral dose sufficient for clinical efficacy with as little virus as possible (to limit toxicity). A new reporter gene based on the sodium iodide symporter (NIS) will be characterized with regard to its ability to monitor therapeutic gene expression and contrasted with other measurements of catalytic activity under development. There are three specific aims of the proposed studies. 1. Compare the distribution of NIS reporter gene expression to that of CD/HSV-1 TK therapeutic gene expression. If it can be shown that NIS activity is a surrogate marker of therapeutic gene expression, NIS imaging could eliminate the biopsy currently used to assess transgene expression and allow for dynamic and whole body monitoring of transgene expression. 2. Evaluate new vector formulations and injections conditions designed to optimize placement of the adenovirus within the prostate to obtain maximal organ coverage. This work will provide the scientific basis for a clinical trial described in Project 3. 3. Contrast the prodrug-labeled approach of monitoring transgene expression to the NIS approach.
This aim tests the hypothesis that the bystander effect can be measured and exceeds the area of gene expression. Bystander effect will be measured using autoradiography of bound radiolabeled prodrugs ([3H]-ganciclovir-MP, [14C]-5-FdUMP) and compared to iodide localization following transduction of NIS. Finally the measurements will be extended to non-invasive techniques using [19F]-MR chemical shift imaging of 5-FU and 123(I)uptake using SPECT imaging of NIS activity. A large animal model is needed for the proposed studies. We plan to use the prostates of large, mongrel dogs. The studies described represent """"""""proof of principle"""""""" and will generate significant new knowledge that will benefit the gene therapy and medical communities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA097012-05
Application #
7667319
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
5
Fiscal Year
2008
Total Cost
$241,256
Indirect Cost
Name
Henry Ford Health System
Department
Type
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Freytag, Svend O; Stricker, Hans; Lu, Mei et al. (2014) Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 89:268-76
Lu, Mei; Freytag, Svend O; Stricker, Hans et al. (2011) Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemp Clin Trials 32:453-60
Barton, Kenneth N; Stricker, Hans; Elshaikh, Mohamed A et al. (2011) Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 19:1353-9
Kumar, Sanath; Freytag, Svend O; Barton, Kenneth N et al. (2010) A novel method of boron delivery using sodium iodide symporter for boron neutron capture therapy. J Radiat Res 51:621-6
Siddiqui, Farzan; Kolozsvary, Andrew; Barton, Kenneth N et al. (2009) Does hyperthermia increase adenoviral transgene expression or dissemination in tumors? Int J Hyperthermia 25:273-9
Freytag, Svend O; Movsas, Benjamin; Aref, Ibrahim et al. (2007) Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15:1016-23
Siddiqui, Farzan; Barton, Kenneth N; Stricker, Hans J et al. (2007) Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. Hum Gene Ther 18:312-22
Freytag, Svend O; Stricker, Hans; Movsas, Benjamin et al. (2007) Prostate cancer gene therapy clinical trials. Mol Ther 15:1042-52
Freytag, Svend O; Stricker, Hans; Peabody, James et al. (2007) Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15:636-42
Freytag, Svend O; Barton, Kenneth N; Brown, Stephen L et al. (2007) Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 15:1600-6

Showing the most recent 10 out of 15 publications